key: cord-0794055-elj4glp1 authors: Elseginy, Samia A.; Fayed, Bahgat; Hamdy, Rania; Mahrous, Noura; Mostafa, Ahmed; Almehdi, Ahmed M.; S. M. Soliman, Sameh title: Promising anti-SARS-CoV-2 drugs by effective dual targeting against the viral and host proteases date: 2021-05-10 journal: Bioorg Med Chem Lett DOI: 10.1016/j.bmcl.2021.128099 sha: f312a6803c7b036da0264fcb05886f1289ed6e0b doc_id: 794055 cord_uid: elj4glp1 SARS-CoV-2 caused dramatic health, social and economic threats to the globe. With this threat, the expectation of future outbreak, and the shortage of anti-viral drugs, scientists were challenged to develop novel antivirals. The objective of this study is to develop novel anti-SARS-CoV-2 compounds with dual activity by targeting valuable less-mutated enzymes. Here, we have mapped the binding affinity of >500,000 compounds for potential activity against SARS-CoV-2 main protease (Mpro), papain protease (PLpro) and human furin protease. The enzyme inhibition activity of most promising hits was screened and tested in vitro on SARS-CoV-2 clinical isolate incubated with Vero cells. Computational modelling and toxicity of the compounds were validated. The results revealed that 16 compounds showed potential binding activity against Mpro, two of them showed binding affinity against PLpro and furin protease. Respectively, compounds 7 and 13 showed inhibition activity against Mpro at IC50 0.45 and 0.11µM, against PLpro at IC50 0.085 and 0.063µM, and against furin protease at IC50 0.29µM. Computational modelling validated the binding affinity against all proteases. Compounds 7 and 13 showed significant inhibition activity against the virus at IC50 0.77 and 0.11µM, respectively. Both compounds showed no toxicity on mammalian cells. The data obtained indicated that compounds 7 and 13 exhibited potent dual inhibition activity against SARS-CoV-2. The dual activity of both compounds can be of great promise not only during the current pandemic but also for future outbreaks since the compounds’ targets are of limited mutation and critical importance to the viral infection. SARS-CoV-2 caused dramatic health, social and economic threats to the globe. With 27 this threat, the expectation of future outbreak, and the shortage of anti-viral drugs, scientists 28 were challenged to develop novel antivirals. The objective of this study is to develop novel 29 anti-SARS-CoV-2 compounds with dual activity by targeting valuable less-mutated enzymes. 30 Here, we have mapped the binding affinity of >500,000 compounds for potential activity 31 against SARS-CoV-2 main protease (M pro ), papain protease (PLpro) and human furin protease. 32 The enzyme inhibition activity of most promising hits was screened and tested in vitro on This makes the selected molecules obtained from this filtration step are unlikely toxic. Around 1350 compounds were selected based on 7 pharmacophore features of M pro . This was 84 followed by molecular docking against the binding pockets of M pro , PLpro and furin. Around 85 100 compounds (Suppl. showed partial inhibition activity with inhibition percentage 31±2 and 26.44±1.9, 161 respectively ( Fig. 4A) . Following the primary screening, compounds 7 and 13 were further 162 tested in dose-response curve. The data showed that IC 50 of compounds 7 and 13 were 0.45 163 and 0.11 µM, respectively ( Fig. 4B and C) . These results indicated that both compounds 164 particularly 13 were more potent against SARS-CoV-2 M pro . The inhibition activity of the 16 compounds was further tested against SARS-CoV-2 166 PLpro ( Fig. 4D and Suppl. Table 2 ). Interestingly, compound 13 showed 80%±4 (P < 167 0.0001) inhibition activity, while compound 7 exerted 56.4%±0.3 (P < 0.0001) inhibition 168 activity (Fig. 4D) . Compound 1, 2, 8, 9 and 12 showed lower inhibition activity of not more 169 than 40% (Fig. 4D) . On the other hand, despite the reported anti-HIV activity of compound Compounds 7 and 13 were further evaluated against furin protease (Fig. 5A) . The 188 data indicated that compounds 7 and 13 showed potential inhibition activity against the 189 enzyme with IC 50 0.29 µM ( Fig. 5B and C) . The data display the mean of the percentage of the enzyme inhibition ± SEM of 3 replicas. Table 2 . The docking study against M pro revealed that compounds 7 and 13 208 formed H-bonds with Asn142, while compound 7 formed H-bonds with Thr24, Thr25, and 209 Gln189 ( Fig. 7A and Suppl. Fig. 1A) . Compound 13 formed H-bond with the key residue 210 Glu166, and π-π interaction with His41 ( Fig. 7B and Suppl. Fig. 1B) . Both compounds showed 211 hydrophobic interactions with Met49 and Ile141. Compounds 7 and 13 showed good interaction within PLpro binding site. Both compounds 213 formed H-bond with Lys157 and π-π interaction with Pro284 and Tyr264 (Fig. 7C, D, and 214 Suppl. Fig. 1C, D) . Furthermore, compounds 7 and 13 formed H-bonds with His364 and 215 Thr365 of furin protease, while compounds 13 showed additional two H-bonds with Asn295 216 and Thr368 (Fig. 8A, B, and Suppl. Fig. 1E, F) . We can conclude that compounds 7 and 13 showed strong H-bonds profile and hydrophobic 229 interactions with the three enzymes; however, compounds 13 showed better binding modes 230 than compound 7 and this may explain the potential higher activity of compound 13. pp1a and pp1ab polyproteins to functional proteins, which is critical for viral replication [21] . The peptidomimetic-like approach employed in this study by designing drug-like In conclusion, the multi-targeting activity, selectivity and promising in vitro inhibition 307 activity of the discovered compounds from this study make them excellent lead compounds Zhang, Genetically Engineered Cell-Derived Nanoparticles for Targeted Breast Cancer 375 Immunotherapy, Molecular Therapy, 28 (2020) 536-547. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, The Lancet Therapeutic and triage strategies 331 for 2019 novel coronavirus disease in fever clinics Drug treatment options for the 2019-new coronavirus (2019-nCoV) COVID-19 338 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines 339 and therapeutics Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by 341 blocking the trimerization of viral spike glycoprotein? FDA-Approved Drugs with Severe Acute Respiratory Syndrome Coronavirus 2 Prevention, Coronavirus Disease Drug repurposing for coronavirus 350 (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and 351 protease enzymes Drug Development 353 and Medicinal Chemistry Efforts toward SARS-Coronavirus and Covid-19 Therapeutics Structure, 356 function, and antigenicity of the SARS-CoV-2 spike glycoprotein The spike 358 glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent 359 in CoV of the same clade The crystal structure of the proprotein processing proteinase furin explains its 362 stringent specificity Protective role for the N-terminal domain of α-365 dystroglycan in Influenza A virus proliferation Crystal structure of SARS-CoV-2 main protease provides a basis for design 369 of improved α-ketoamide inhibitors Antiviral agents against COVID-19: structure-based design of 371 specific peptidomimetic inhibitors of SARS-CoV-2 main protease Discovery of structurally diverse HIV-1 integrase inhibitors based on 378 a chalcone pharmacophore Proteases and protease 380 inhibitors in infectious diseases Analysis of therapeutic targets for SARS-CoV-2 and discovery 383 of potential drugs by computational methods Conservation of substrate specificities among coronavirus main 386 proteases The SARS-CoV-2 main protease as drug target, Bioorganic & 388 Medicinal Chemistry Letters Inhibition of SARS-CoV-2 main 391 protease by phenolic compounds from Manilkara hexandra (Roxb.) Dubard assisted by 392 metabolite profiling and in silico virtual screening The 395 role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the 396 presence or absence of trypsin The spike 398 glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent 399 in CoV of the same clade Development and testing of druglike screening libraries Lopinavir/ritonavir A Trial of Lopinavir-Ritonavir in Adults Hospitalized with 410 Severe Covid-19 Potent Noncovalent Inhibitors of 413 the Main Protease of SARS-CoV-2 from Molecular Sculpting of the Drug Perampanel